Unkategorisiert

Artificial intelligence (AI) is a driver of digital transformation – but it also entails risks.

The Charging Point Data Ordinance was issued by the Federal Ministry for Climate Action, Environment, Energy, Mobility, Innovation and Technology on the basis of Section 4a (3) of the Federal Act on the Establishment of Uniform Standards for the Development of Infrastructure for Alternative Fuels.

Dominik Göbel and Harald Nemec, partner at Schwarz & Partner, Patentanwälte GmbH, have co-authored the Austrian contribution to the book ‘Stief/Matschke, Infringement of Second Medical Use Claims’.

The Austrian Supreme Court (OGH) ruled in the case of a grid operator that charged a grid access fee for two photovoltaic systems installed on a company site that no new grid access fee was due for the existing grid connection that was already being used to purchase electricity.

Generally, only the author (or the person entitled to use the work) of a work is entitled to exploit it. This exclusive right includes, among other things, the reproduction of the work, which already includes the creation of a digital copy for storage. Exploitation of the work by third parties is not permitted unless the author consents to this or there is a legal exception.

The artificial intelligence Dall E 2 generates controversy. Photographers, illustrators and designers feel threatened, because with Dall E 2, images can be created by text input. Uncomplicated and but with open legal questions.

On 19.11.2021, the Austrian Parliament took one of the last steps necessary for implementing the EU-wide unitary patent and opening the Unified Patent Court.

Parallel to the trademark system, there is an independent and far-reaching protection for protected geographical indications (hereinafter PGI) and protected designations of origin (hereinafter PDO).

The IP-Team at Gassauer-Fleissner has contributed the Austrian Chapter on design rights in the International Comparative Legal Guide by glg.

Supplementary Protection Certificates (SPCs) effectively extend the protection afforded by patents for medicinal products by up to 5 years.